Destiny Pharma Sees Potential For XF-73 In Oral Mucositis
Added Indication For Phase III-Ready Asset
Executive Summary
A new research program exploring an additional indication for XF-73 will help the UK biotech's licensing discussions for the nasal gel.
You may also be interested in...
Pharma Firms Welcome 'Pragmatic' EU Reforms But Concerns Persist
The European parliament has voted for legislation it says will lead to fairer, more accessible healthcare. The continent's drugmakers are still not wholly convinced.
Sector Stalwart Appalled At Lack Of UK Investor Interest In Biotech
Ali Mortazavi, CEO of e-therapeutics, says the RNAi specialist is delisting from AIM and describes the UK markets as “completely broken and closed” to biotech firms.
Novartis Flies The Flag For US Despite More Job Cuts
It is still “a priority country,” the Switzerland-based giant tells Scrip, as around 240 jobs face the axe at Novartis’s development organizational unit across the Atlantic.